Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Combination With Paclitaxel in Small Cell Lung Cancer
NCT07465757Phase 2Recruiting
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of alisertib in small cell lung cancer (SCLC) (5 cohorts), sponsored by Puma Biotechnology, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 24 months. Started Sep 2026; status: recruiting.
02
Drugs
alisertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07465757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465757.